This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Horizon Therapeutics Public Limited Company
Horizon Therapeutics Public Limited Company, often referred to simply as Horizon Therapeutics, is a biopharmaceutical firm headquartered in Ireland (IE). Founded in 2008, the company has rapidly established itself within the global pharmaceutical industry, focusing on the development and commercialisation of innovative medicines for rare and rheumatic diseases. Horizon Therapeutics is renowned for its core products, including Tepezza and Krystexxa, which address significant unmet medical needs. These therapies are distinguished by their unique mechanisms of action and commitment to improving patient outcomes. With a strong market position, Horizon has achieved notable milestones, including strategic acquisitions that have expanded its portfolio and global reach, particularly in North America and Europe.
DitchCarbon Score
How does Horizon Therapeutics Public Limited Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Horizon Therapeutics Public Limited Company's score of 52 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Horizon Therapeutics Public Limited Company, headquartered in Ireland (IE), currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Amgen Inc., and any emissions data or climate commitments may be inherited from this parent organisation. As part of its climate initiatives, Horizon Therapeutics is aligned with the sustainability efforts of Amgen Inc., which has established various reduction targets and commitments. However, specific reduction targets or achievements for Horizon Therapeutics have not been disclosed. The company is involved in broader industry climate initiatives, including those set forth by the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are linked to Amgen Inc. at the first cascade level. This indicates that Horizon Therapeutics is likely to follow the sustainability framework and targets established by its parent company. In summary, while specific emissions data and reduction targets for Horizon Therapeutics are not available, the company is positioned within a corporate family that prioritises climate action and sustainability through its association with Amgen Inc.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 144,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 290,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Horizon Therapeutics Public Limited Company is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
